IRCT138803272042N1
Completed
Phase 3
The efficacy of Cerebrolysin in the treatment of acute ischemic stroke
Research Deputy, Shahid Beheshti University of Medical Sciences0 sites100 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Cerebral infarction.
- Sponsor
- Research Deputy, Shahid Beheshti University of Medical Sciences
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients aged 45 to 85 years, the occurrence of acute cerebral ischemic attack (embolic or thrombotic), hospitalization during 12 hours of first symptoms of stroke, systolic blood pressure less than 200 and diastolic less than 100 mmHg
Exclusion Criteria
- •recovery of neurologic symptoms after 4 hours of attack, hemorrhagic stroke or the occurrence of stroke in vertebrobasilar system with blood pressure \=200/100 mmHg, seizures, Papilledema or rising intracranial pressure (RICP), neck stiffness or symptoms of brain stimulation, the condition of consciousness stupor and coma (GCS \= 6\), acute myocardial infarction, National Institutes of Health Stroke Scale (NIHSS) less than 7 and more than 24, hepatic or renal failure \- heart failure, dementia initial appearance, acute infectious disease, doubt the Involvement in subsequent brain area (posterior circulation), pregnant women, symptoms of progressive neurologic defects, patients who are in other trials, patients received piracetam or calcium channel blockers (CCB), Patients who received r\-TPA treatment during first 4 hours of symptoms
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Is Cerebrolysin efficient in neurorecovery after moderate-severe traumatic brain injury?Moderate-severe traumatic brain injuryMedDRA version: 26.1Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2022-003382-38-ROFSNANO05012022440
Recruiting
Not Applicable
Efficacy of Cerebrolysin as an Adjuvant Therapy Following Mechanical Thrombectomy in Patients with Large Vessel Occlusion StrokeNervous System DiseasesPACTR202306562134107Ain Shams University hospital50
Active, not recruiting
Phase 4
sing a neuroprotective drug to treat patients who have a serious type of brain bleeding caused by a rupture of a weakened blood vessel (aneurysm)ISRCTN16818128niversity Hospital Centre Zagreb50
Completed
Phase 2
Clinical study to assess treatment effects of Cerebrolysin in amyotrophic lateral sclerosisISRCTN38393880Instituto Cardiológico Banfield20
Completed
Not Applicable
The effect of cerebrolysin on patients with head trauma and brain injuryDiffuse brain injury.IRCT2014040312888N2Tabriz University of Medical Sciences52